Piper Sandler Maintains Overweight on AtriCure, Raises Price Target to $60
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst Matt O'Brien maintains AtriCure (NASDAQ:ATRC) with a Overweight and raises the price target from $50 to $60.
Piper Sandler analyst Matt O'Brien maintains AtriCure (NASDAQ:ATRC) with a Overweight and raises the price target from $50 to $60.